Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rigo I Acevedo"'
Autor:
Alexander S Carlson, Rigo I Acevedo, Daniel M Lim, Roman Gulati, Agnes Gawne, Alexandra O Sokolova, Heather H Cheng, Peter S Nelson, R Bruce Montgomery, Evan Y Yu, Michael T Schweizer
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239686 (2020)
IntroductionA significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility
Externí odkaz:
https://doaj.org/article/f6c10cf143e14114ba66811e4329fc74
Autor:
Heather H. Cheng, Michael T. Schweizer, Daniel M. Lim, Evan Y. Yu, Rigo I. Acevedo, Agnes M. Gawne, R. Bruce Montgomery, Alexander S. Carlson, Alexandra O. Sokolova, Roman Gulati, Peter S. Nelson
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239686 (2020)
PLoS ONE
PLoS ONE
IntroductionA significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::274a94ee45cc0e0d63207f14fa0ae489
https://doaj.org/article/f6c10cf143e14114ba66811e4329fc74
https://doaj.org/article/f6c10cf143e14114ba66811e4329fc74
Autor:
Rigo I. Acevedo, Daniel M. Lim, Alex S. Carlson, Evan Y. Yu, Michael T. Schweizer, Roman Gulati
Publikováno v:
Journal of Clinical Oncology. 38:172-172
172 Background: Nearly 25% of patients with mCRPC harbor DDR alterations, with some of these mutations associating with increased tumor susceptibility to PARP inhibitors and platinum-based chemotherapies. While, mutations in some DDR genes (e.g. BRCA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88d92a022a7d01a816bfc42337b0e14
https://doi.org/10.1200/jco.2020.38.6_suppl.172
https://doi.org/10.1200/jco.2020.38.6_suppl.172